Characteristic | Ischaemic stroke | |
HR (95% CI) | P value | |
Demographics | ||
Age (years) | 1.04 (1.03 to 1.05) | <0.001 |
Age >75 years | 1.89 (1.44 to 2.48) | <0.001 |
Sex (male) | 0.74 (0.56 to 0.97) | 0.03 |
Body mass index | 0.99 (0.97 to 1.01) | 0.37 |
History variables | ||
Hypertension | 1.46 (1.08 to 1.98) | 0.02 |
Diabetes mellitus | 1.13 (0.81 to 1.58) | 0.48 |
Prior myocardial infarction | 1.46 (1.04 to 2.07) | 0.03 |
Prior CABG | 1.56 (1.09 to 2.22) | 0.01 |
Stroke or TIA | 2.54 (1.82 to 3.53) | <0.001 |
Congestive heart failure | 1.19 (0.90 to 1.56) | 0.22 |
Cardiomyopathy | 0.64 (0.45 to 0.92) | 0.02 |
Smoking (current or former) | 1.00 (0.76 to 1.31) | 0.99 |
Chronic lung disease | 0.99 (0.64 to 1.52) | 0.95 |
Obstructive sleep apnoea | 1.02 (0.72 to 1.45) | 0.91 |
Peripheral arterial disease | 1.46 (0.98 to 2.17) | 0.06 |
CHA2DS2-VASc score | 1.32 (1.21 to 1.44) | <0.001 |
Preprocedural haemodynamics | ||
Heart rate | 1.00 (0.99 to 1.01) | 0.67 |
Duration of AF episode | – | 0.32 |
<48 hour | 0.97 (0.71 to 1.31) | 0.83 |
<24 hours | 2.72 (0.83 to 8.89) | 0.10 |
24–48 hours | 2.37 (0.74 to 7.57) | 0.15 |
>2 days to <7 days | 2.15 (0.68 to 6.77) | 0.19 |
Preprocedural medications | ||
Beta blocker | 1.24 (0.93 to 1.64) | 0.14 |
Calcium channel blocker (non-dihydropyridine) | 1.45 (1.10 to 1.90) | 0.008 |
Statin | 0.97 (0.72 to 1.29) | 0.81 |
ACE-I or ARB | 1.16 (0.88 to 1.52) | 0.29 |
Antiplatelets | 1.07 (0.82 to 1.40) | 0.64 |
Warfarin or NOACs | 0.90 (0.68 to 1.22) | 0.52 |
Antiarrhythmics | 0.81 (0.60 to 1.10) | 0.18 |
Echocardiography | ||
Patent foramen ovale | 0.81 (0.57 to 1.16) | 0.24 |
Patent foramen ovale shunt direction | – | 0.01 |
*No PFO | – | – |
Right-to-left | 1.74 (1.06–2.86) | 0.03 |
Left-to-right | 0.59 (0.36–0.94) | 0.03 |
Bidirectional | 0 | 0.97 |
Mean LAA emptying velocity | 0.99 (0.98 to 0.996) | 0.003 |
Spontaneous echo contrast (LA or LAA) | 1.68 (1.24 to 2.27) | <0.001 |
Left atrial appendage thrombus | 2.53 (1.19 to 5.37) | 0.02 |
Severe left atrial enlargement | 0.95 (0.72 to 1.27) | 0.75 |
LV ejection fraction | 1.01 (0.99 to 1.02) | 0.37 |
Mitral regurgitation (>=moderate) | 1.36 (1.02 to 1.81) | 0.04 |
Discharge medications | ||
Beta blocker | 1.30 (0.98 to 1.73) | 0.07 |
Calcium channel blocker (non-dihydropyridine) | 1.29 (0.94 to 1.78) | 0.12 |
Statin | 0.95 (0.71 to 1.26) | 0.71 |
ACE-I or ARB | 1.17 (0.90 to 1.53) | 0.25 |
Antiplatelets | 0.95 (0.72 to 1.24) | 0.69 |
Warfarin or NOACs | 1.04 (0.68 to 1.60) | 0.86 |
Antiarrhythmics | 0.89 (0.66 to 1.18) | 0.41 |
INR at discharge | 1.03 (0.87 to 1.23) | 0.74 |
* Reference category
ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; CABG, coronary artery bypass grafting; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischaemic attack (doubled), vascular disease, age 65 to 74, female; INR, international normalised ratio; LA, left atrial; LAA, left atrial appendage; LV, left ventricular; NOACs, novel oral anticoagulants; PFO, patent foramen ovale; TIA, transient ischaemic attack.